HiLung Inc.’s Initiatives Featured in Nature

HiLung Inc. (Head Office: Kyoto, Japan; CEO: Yuki Yamamoto), a company advancing next-generation respiratory drug discovery support based on human iPSC-derived lung organoid technology, is pleased to announce that its work has been featured in an online advertorial article published by the international scientific journal Nature as part of its Technology Feature: Organoids series, in the article entitled “Lung organoids could speed development of treatments” (published May 15, 2025).

The advertorial highlights HiLung’s proprietary lung organoid platform, with particular attention to its ability to recapitulate the complex cellular composition and functional characteristics of the human lung that conventional cell line-based approaches have been unable to fully capture. The article also introduces the platform’s potential applications in drug discovery, toxicity assessment, and personalized medicine.

By combining regenerative medicine-based in vitro organ models with advanced analytical technologies such as single-cell and spatial omics, HiLung is working to elucidate disease mechanisms and develop innovative therapies for intractable respiratory diseases, including pulmonary fibrosis/interstitial lung disease, COPD, cystic fibrosis, respiratory infections, and lung cancer. This feature in Nature reflects the growing international recognition of our efforts and is expected to further accelerate our business development and academic collaborations.

▼Link to the Nature advertorial:
https://www.nature.com/articles/d42473-025-00084-z

HiLung will continue to contribute to the advancement of science and medicine through the implementation of innovative platforms aimed at overcoming respiratory diseases.